Haemonetics Corporation (NYSE:HAE) is Royce & Associates LP's 8th Largest Position

Royce & Associates LP boosted its position in shares of Haemonetics Corporation (NYSE:HAE - Free Report) by 0.7% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,161,296 shares of the medical instruments supplier's stock after acquiring an additional 8,028 shares during the quarter. Haemonetics accounts for 0.8% of Royce & Associates LP's portfolio, making the stock its 8th biggest holding. Royce & Associates LP owned 2.31% of Haemonetics worth $73,800,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of HAE. TD Waterhouse Canada Inc. bought a new position in Haemonetics during the fourth quarter valued at approximately $25,000. Covestor Ltd increased its holdings in Haemonetics by 146.8% during the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock worth $58,000 after purchasing an additional 439 shares during the period. KBC Group NV boosted its position in Haemonetics by 19.9% during the 1st quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier's stock valued at $154,000 after acquiring an additional 401 shares in the last quarter. Vise Technologies Inc. boosted its position in Haemonetics by 8.7% during the 4th quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier's stock valued at $221,000 after acquiring an additional 225 shares in the last quarter. Finally, CWC Advisors LLC. boosted its position in shares of Haemonetics by 7.4% in the 4th quarter. CWC Advisors LLC. now owns 3,083 shares of the medical instruments supplier's stock worth $241,000 after purchasing an additional 212 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Haemonetics Trading Down 0.7%

HAE stock traded down $0.56 during midday trading on Thursday, hitting $74.01. The stock had a trading volume of 59,667 shares, compared to its average volume of 748,868. The firm has a market cap of $3.56 billion, a PE ratio of 22.36, a price-to-earnings-growth ratio of 1.20 and a beta of 0.39. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.62 and a quick ratio of 0.99. Haemonetics Corporation has a 12-month low of $55.30 and a 12-month high of $94.99. The company's 50-day moving average price is $71.93 and its 200 day moving average price is $67.84.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating analysts' consensus estimates of $1.22 by $0.02. The company had revenue of $330.60 million for the quarter, compared to analyst estimates of $329.38 million. Haemonetics had a net margin of 12.32% and a return on equity of 26.37%. Haemonetics's revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter last year, the business earned $0.90 EPS. On average, equities research analysts predict that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HAE has been the subject of a number of recent research reports. Raymond James Financial reiterated a "strong-buy" rating and set a $105.00 price objective (down previously from $115.00) on shares of Haemonetics in a research note on Friday, May 9th. Needham & Company LLC decreased their price target on Haemonetics from $104.00 to $84.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Robert W. Baird started coverage on Haemonetics in a research report on Thursday, June 26th. They set an "outperform" rating and a $87.00 price objective on the stock. Citigroup raised Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 target price on the stock in a report on Wednesday, July 9th. Finally, Barrington Research reiterated an "outperform" rating and set a $95.00 target price on shares of Haemonetics in a research note on Friday, July 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $97.30.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.